세계 경피 약물전달 시스템 시장 - 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 지역별 부문 예측(2024-2030년)

Transdermal Drug Delivery Systems Market Growth & Trends:

The global transdermal drug delivery systems market size is anticipated to reach to reach USD 145.04 billion by 2030, expanding at a CAGR of 11.9%, based on a new report by Grand View Research, Inc. The growing acceptance of transdermal patches, particularly for conditions like diabetes that necessitate consistent and daily insulin dosage, is projected to drive market growth in the transdermal drug delivery systems sector.

In addition, diabetes patients require regular insulin administration, traditionally done through injections, which can cause discomfort and increase the risk of disease transmission. This makes transdermal drug delivery system will be a more appealing alternative for delivering insulin.Another significant factor contributing to the growth of the market is the rising demand for painless drug delivery. The constant use of injections for insulin administration can lead to discomfort and even chronic diseases. Transdermal patches offer a more comfortable and efficient way of delivering insulin, thus addressing these issues.

Moreover, chronic diseases like diabetes, heart conditions, and pain-related issues become more common globally, there is a greater need for drug delivery methods that are both effective and easy for patients to use. For example, according to the American Heart Association's 2022 report on the Global Burden of Disease, the death rate per 100,000 people was 239.8, while the prevalence rate was 7354.1 per 100,000. Transdermal drug delivery systems come with multiple benefits such as being non-invasive, providing controlled drug release, enhancing patient adherence, and minimizing side effects. This increasing demand for user-friendly drug delivery systems, particularly for the ongoing management of long-term medications, is driving the transdermal drug delivery market growth.

Transdermal Drug Delivery Systems Market Report Highlights:

• In 2023, the iontophoresis segment accounted for the largest market share. This can be attributed due to its effectiveness in delivering medications non-invasively through the skin using electrical currents
• In 2023, the pain management segment led the application segment due to the increasing prevalence of chronic diseases and trauma, including musculoskeletal disorders such as arthritis, osteoarthritis, and orthopedic degenerative disorders. The growing prevalence of these conditions is contributing, driving the segment growth
• The hormone segment is expected to grow at an exponential CAGR during the forecast period in the application segment in 2023. This is due to rising demand for convenient hormone therapies. Transdermal delivery's effectiveness and user-friendliness make it an attractive solution for administering hormones
• The North American region held the largest market share in 2023 due to advanced healthcare infrastructure and high prevalence of targeted diseases like chronic pain, central nervous system disorders, and cardiovascular diseases in the region
• Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas

Table of Contents

Chapter 1. Transdermal Drug Delivery Systems Market: Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Technology
  • 1.1.2. Application
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Transdermal Drug Delivery Systems Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transdermal Drug Delivery Systems Market: Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing adoption of transdermal patches
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. High demand for pain free drug delivery
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of transdermal technology
    • 3.2.2.2. Limited number of approved medications
• 3.3. Transdermal Drug Delivery System Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Transdermal Drug Delivery Systems Market: Technology Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. Electroporation
  • 4.1.2. Radio Frequency
  • 4.1.3. Iontophoresis
  • 4.1.4. Microporation
  • 4.1.5. Thermal
  • 4.1.6. Mechanical arrays
  • 4.1.7. Ultrasound
  • 4.1.8. Others
• 4.2. Technology Market Share, 2023 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Transdermal Drug Delivery System Market by Technology Outlook
• 4.5. Market Application & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Electroporation
    • 4.5.1.1. Market estimates and forecast 2018 - 2030 (Revenue in USD Million)
  • 4.5.2. Radio Frequency
    • 4.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.3. Iontophoresis
    • 4.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.4. Microporation
    • 4.5.4.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.5. Thermal
    • 4.5.5.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.6. Mechanical Arrays
    • 4.5.6.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.7. Ultrasound
    • 4.5.7.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 4.5.8. Others
    • 4.5.8.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)

Chapter 5. Transdermal Drug Delivery System Market: Application Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. CNS
  • 5.1.2. Pain Management
  • 5.1.3. Cardiovascular
  • 5.1.4. Hormone
  • 5.1.5. Immunological
  • 5.1.6. Metabolic
  • 5.1.7. Gastrointestinal
  • 5.1.8. Infection
  • 5.1.9. Cancer
  • 5.1.10. Others
• 5.2. Application Market Share, 2023 & 2030
• 5.3. Segment Dashboard
• 5.4. Global Transdermal Drug Delivery System Market by Application Outlook
• 5.5. Market Application & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5.1. CNS
    • 5.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.2. Pain Management
    • 5.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.3. Cardiovascular
    • 5.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.4. Hormone
    • 5.5.4.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.5. Immunological
    • 5.5.5.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.6. Metabolic
    • 5.5.6.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.7. Gastrointestinal
    • 5.5.7.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.8. Infection
    • 5.5.8.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.9. Cancer
    • 5.5.9.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)
  • 5.5.10. Others
    • 5.5.10.1. Market estimates and forecast, 2018 - 2030 (Revenue in USD Million)

Chapter 6. Transdermal Drug Delivery System Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Competitive scenario
    • 6.5.1.3. Regulatory framework
    • 6.5.1.4. Reimbursement scenario
    • 6.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Competitive scenario
    • 6.6.1.3. Regulatory framework
    • 6.6.1.4. Reimbursement scenario
    • 6.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Competitive scenario
    • 6.6.4.3. Regulatory framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Competitive scenario
    • 6.6.5.3. Regulatory framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Competitive scenario
    • 6.6.6.3. Regulatory framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Competitive scenario
    • 6.6.7.3. Regulatory framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Competitive scenario
    • 6.6.8.3. Regulatory framework
    • 6.6.8.4. Reimbursement scenario
    • 6.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Competitive scenario
    • 6.7.1.3. Regulatory framework
    • 6.7.1.4. Reimbursement scenario
    • 6.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Competitive scenario
    • 6.7.6.3. Regulatory framework
    • 6.7.6.4. Reimbursement scenario
    • 6.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Competitive scenario
    • 6.8.1.3. Regulatory framework
    • 6.8.1.4. Reimbursement scenario
    • 6.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Competitive scenario
    • 6.8.2.3. Regulatory framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Competitive scenario
    • 6.8.3.3. Regulatory framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Competitive scenario
    • 6.9.1.3. Regulatory framework
    • 6.9.1.4. Reimbursement scenario
    • 6.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Competitive scenario
    • 6.9.2.3. Regulatory framework
    • 6.9.2.4. Reimbursement scenario
    • 6.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Competitive scenario
    • 6.9.3.3. Regulatory framework
    • 6.9.3.4. Reimbursement scenario
    • 6.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Competitive scenario
    • 6.9.4.3. Regulatory framework
    • 6.9.4.4. Reimbursement scenario
    • 6.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Novartis AG
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Johnson & Johnson
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Mylan Pharmaceuticals, Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Boehringer Ingelheim GmbH
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. AbbVie
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Grunenthal
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Skyepharma
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. 3M Company
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Noven Pharmaceuticals, Inc.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. 4P Therapeutics, LLC
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Hisamitsu Pharmaceutical co. Inc
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives